Stock ANEB ANEBULO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Anebulo Pharmaceuticals, Inc.

Equities

ANEB

US0345691036

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 06/05/2024 BST 		5-day change 1st Jan Change
2.95 USD 0.00% Intraday chart for Anebulo Pharmaceuticals, Inc. +7.27% +21.90%
02-13 Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
2023 Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI

Valuation

Fiscal Period: June 2021 2022 2023 2024 2025 2026
Capitalization 1 159.2 121.4 60.24 76.5 - -
Enterprise Value (EV) 1 159.2 121.4 60.24 76.5 76.5 76.5
P/E ratio -2.41 x -17.9 x -5 x -6.65 x -5.36 x -4.34 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / FCF - -22,314,660 x - - - -
FCF Yield - -0% - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 23,345 23,345 25,633 25,933 - -
Reference price 2 6.820 5.200 2.350 2.950 2.950 2.950
Announcement Date 22/09/21 09/09/22 20/09/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - -
EBITDA - - - - - -
EBIT 1 -3.614 -6.831 -11.78 -11.93 -18.01 -24.52
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -30.25 -6.826 -11.73 -11.77 -17.88 -24.36
Net income 1 -38.46 -6.826 -11.73 -11.77 -17.88 -24.36
Net margin - - - - - -
EPS 2 -2.830 -0.2900 -0.4700 -0.4433 -0.5500 -0.6800
Free Cash Flow - -5.44 - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 22/09/21 09/09/22 20/09/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - -
EBITDA - - - - - - - - - - - -
EBIT 1 -1.555 -1.071 -1.88 -2.325 -2.612 -3.813 -2.864 -2.494 -2.544 -2.76 -3.038 -3.589
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -1.553 -1.073 -1.876 -2.323 -2.612 -3.827 -2.798 -2.496 -2.481 -2.717 -3.007 -3.563
Net income 1 -1.553 -1.073 -1.876 -2.323 -2.612 -3.827 -2.798 -2.496 -2.481 -2.717 -3.007 -3.563
Net margin - - - - - - - - - - - -
EPS 2 -0.0700 -0.0500 -0.0800 -0.1000 -0.1100 -0.1500 -0.1100 -0.1000 -0.1000 -0.1100 -0.1167 -0.1233
Dividend per Share - - - - - - - - - - - -
Announcement Date 12/11/21 11/02/22 11/05/22 09/09/22 10/11/22 10/02/23 11/05/23 20/09/23 14/11/23 13/02/24 - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -5.44 - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share 2 -0.3600 -0.2300 -0.3900 -0.3800 - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 22/09/21 09/09/22 20/09/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.95 USD
Average target price
6 USD
Spread / Average Target
+103.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ANEBULO PHARMACEUTICALS, INC. Stock Anebulo Pharmaceuticals, Inc.
+21.90% 76.5M
MODERNA, INC. Stock Moderna, Inc.
+22.81% 46.81B
LONZA GROUP AG Stock Lonza Group AG
+46.56% 41.29B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.88% 41.37B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.33% 26.06B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.00% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.43% 11.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.73% 12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.48% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ANEB Stock
  4. Financials Anebulo Pharmaceuticals, Inc.